|
시장보고서
상품코드
1606458
위마비 치료 시장 : 약물 종류별, 유형별, 투여 경로별, 적응증별, 유통 경로별, 국가별, 지역별 - 산업 분석, 시장 규모, 시장 점유율, 예측(2024-2032년)Gastroparesis Treatment Market, By Drug Class, By Type, By Route of Administration, By Disease Indication, By Distribution Channel, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2024-2032 |
||||||
※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.
보고서 하이라이트
위마비 치료 시장 규모는 2023년 63억 9,043만 달러로 2024년부터 2032년까지 연평균 4.77%의 CAGR로 확대될 전망입니다.
위마비 치료 시장 - 시장 역학
전 세계 당뇨병 유병률 증가로 시장 수요 증가
당뇨병은 위 마비의 주요 원인이기 때문에 전 세계 당뇨병 환자의 증가는 위 마비에 대한 수요를 촉진하고 있습니다. 국제당뇨병연맹의 보고서에 따르면 2021년에는 5억 3,700만 명의 성인이 당뇨병을 앓고 있으며, 2030년에는 6억 4,300만 명으로 증가할 것으로 예측됩니다. 또한, 위마비는 고령층에서 많이 발생하며, 전 세계 고령화 인구의 증가는 위마비 치료 수요를 뒷받침하고 있습니다. 그러나 현재의 위 마비 치료는 증상 치료보다는 증상 관리에 초점을 맞추고 있어 효과가 제한적이고 환자들의 불만족을 초래하고 있습니다. 이는 향후 몇 년간 시장 성장에 걸림돌이 될 수 있습니다. 반면, 위 마비의 근본 원인에 대한 지속적인 연구, 인식 제고 캠페인의 증가, 조기 발견을 개선하기 위한 진단 도구의 발전은 예측 기간 동안 세계 위 마비 치료 시장에 큰 성장 기회를 제공할 것으로 예상됩니다.
위마비 치료 시장 - 주요 인사이트
당사의 리서치 애널리스트가 공유한 분석에 따르면, 세계 시장은 예측 기간(2024-2032년) 동안 연평균 약 4.77%의 CAGR로 매년 성장할 것으로 추정됩니다.
약물 종류별로는 프로키네틱 약물이 2023년 가장 큰 시장 점유율을 차지할 것으로 예측됐습니다.
유형별로는 처방약이 2023년 주요 부문으로 꼽혔습니다.
투여 경로별로는 경구용 의약품이 2023년 주요 부문으로 꼽혔습니다.
적응증별로는 당뇨병성 위마비가 2023년 주요 부문으로 꼽혔습니다.
유통 채널별로는 병원 약국이 2023년 주요 부문으로 꼽혔습니다.
지역별로는 북미 위마비 치료 시장이 2023년 주요 수익원이었습니다.
위마비 치료 시장 - 세분화 분석:
위마비 치료 세계 시장은 약물 종류별, 유형별, 투여 경로별, 적응증별, 유통 채널별, 지역별 시장으로 구분됩니다.
약물 종류에 따라 구토억제제, 운동촉진제, 양성자 펌프 억제제, 기타 4가지로 분류됩니다. 운동 촉진제는 위 근육 수축을 촉진하고 메스꺼움과 같은 증상을 완화하고 소화를 개선하기 때문에 위마비 치료에 매우 중요합니다. 그 효과는 위 마비뿐만 아니라 경장영양을 받고 있는 중증 환자들에게도 도움이 되며, 연구에 따르면 위 마비 환자의 식욕부진을 완화하는 것으로 나타났습니다.
세계 위마비 치료 시장은 유형에 따라 처방약과 일반의약품으로 나뉩니다. 예측 기간 동안 처방약 부문이 시장을 지배할 가능성이 높습니다. 이는 위 마비의 유병률이 증가하고 효과적인 치료에 대한 수요가 증가하고 있기 때문입니다. 처방약은 종종 더 강력하고 증상의 복잡성을 해결하기 위해 특별히 조정되어 의료 서비스 제공자와 환자들 사이에서 채택을 촉진하고 있습니다.
위마비 치료 시장 - 지리적 인사이트
지리적으로 이 시장은 북미, 라틴아메리카, 유럽, 아시아태평양, 중동 및 아프리카에 분포되어 있습니다. 이 지역은 비즈니스를 가져오는 국가별로 더 세분화됩니다.
위마비 치료 시장 - 경쟁 상황:
위마비 유병률의 증가는 혁신적인 치료 옵션에 초점을 맞춘 경쟁 환경을 조성하고 있습니다. 기업들은 운동 촉진제 및 식이 관리 솔루션을 포함한 첨단 치료법을 도입하기 위해 연구 개발을 우선순위에 두고 있습니다. 의료 전문가 및 연구 기관과의 협력은 치료 효과를 높이고 최신 임상 방법의 채택을 촉진하고 있습니다. 또한, 조기 진단과 환자들의 치료 순응도를 높이기 위해 교육적 노력을 통해 인지도를 높이는 것이 필수적입니다. 맞춤형 의료 트렌드도 부상하고 있으며, 환자 개개인의 요구에 더 잘 부합하는 맞춤형 치료 계획을 수립할 수 있게 되었습니다.
목차
제1장 위마비 치료 시장 개요
- 조사 범위
- 시장 추정 연도
제2장 주요 요약
- 시장 내역
- 경쟁 인사이트
제3장 위마비 치료의 주요 시장 동향
- 시장 성장 촉진요인
- 시장 성장 억제요인
- 시장 기회
- 시장 전망 동향
제4장 위마비 치료 산업 연구
- PEST 분석
- Porter's Five Forces 분석
- 성장 전망 매핑
- 규제 프레임워크 분석
제5장 위마비 치료 시장 : 높아지는 지정학적 긴장의 영향
- COVID-19 팬데믹의 영향
- 러시아·우크라이나 전쟁의 영향
- 중동 분쟁의 영향
제6장 위마비 치료 시장 상황
- 위마비 치료 시장 점유율 분석, 2023년
- 주요 제조업체별 내역 데이터
- 기존 기업 분석
- 신흥 기업 분석
제7장 위마비 치료 시장 : 약물 종류별
- 개요
- 약물 종류별 부문 점유율 분석
- 항구토제
- 프로키네틱제
- 양성자 펌프 억제제
- 기타
제8장 위마비 치료 시장 : 유형별
- 개요
- 유형별 부문 점유율 분석
- 처방약
- 시판약
제9장 위마비 치료 시장 : 투여 경로별
- 개요
- 투여 경로별 부문 점유율 분석
- 비강
- 주사제
- 경구
제10장 위마비 치료 시장 : 적응 질환별
- 개요
- 적응 질환별 부문 점유율 분석
- 특발성 위마비
- 당뇨병성 위마비
- 수술후 위마비
제11장 위마비 치료 시장 : 유통 채널별
- 개요
- 유통 채널별 부문 점유율 분석
- 온라인 약국
- 소매 약국
- 병원 약국
제12장 위마비 치료 시장 : 지역
- 소개
- 북미
- 개요
- 북미의 주요 제조업체
- 미국
- 캐나다
- 유럽
- 개요
- 유럽의 주요 제조업체
- 독일
- 이탈리아
- 영국
- 프랑스
- 러시아
- 네덜란드
- 스웨덴
- 폴란드
- 기타
- 아시아태평양(APAC)
- 개요
- 아시아태평양의 주요 제조업체
- 인도
- 중국
- 일본
- 한국
- 호주
- 태국
- 인도네시아
- 필리핀
- 기타
- 라틴아메리카
- 개요
- 라틴아메리카의 주요 제조업체
- 브라질
- 멕시코
- 아르헨티나
- 콜롬비아
- 기타
- 중동 및 아프리카
- 개요
- 중동 및 아프리카의 주요 제조업체
- 사우디아라비아
- 아랍에미리트
- 이스라엘
- 터키
- 알제리
- 이집트
- 기타
제13장 주요 벤더 분석 - 위마비 치료 업계
- 경쟁 대시보드
- Competitive Benchmarking
- Competitive Positioning
- 기업 개요
- Medtronic plc
- Abbott Laboratories
- Salix Pharmaceuticals, Inc.
- Kimberly-Clark Corporation
- CR Bard, Inc
- Boston Scientific Corporation
- Janssen Global Services LLC
- Alfa Wassermann SPA
- AbbVie Inc.
- Evoke Pharma
- Cardinal Health, Inc.
- Rhythm Pharmaceuticals, Inc.
- GlaxoSmithKline Plc
- Bausch Health
- Neurogastrx, Inc.
- Theravance Biopharma
- AstraZeneca Plc
- Cipla Limited
- Pfizer, Inc.
- Teva Pharmaceutical Industries Limited
- The Takeda Pharmaceutical Company Ltd.
- Processa Pharmaceuticals, Inc.
- Vanda Pharmaceuticals, Inc.
- Otsuka Holdings Co. Ltd.
- ANI Pharmaceuticals, Inc.
- CinDome Pharma, Inc.
- PTC Therapeutics
- Ironwood Pharmaceuticals, Inc.
- Others
제14장 애널리스트의 전방위 전망
ksm 24.12.19REPORT HIGHLIGHT
Gastroparesis treatment market size was valued at USD 6,390.43 Million in 2023, expanding at a CAGR of 4.77% from 2024 to 2032.
Gastroparesis is a condition in which the stomach's ability to empty is delayed due to partial paralysis. This causes food to remain in the stomach longer than normal. The gastroparesis treatment focuses on managing delayed stomach emptying, aiming to alleviate symptoms like nausea, vomiting, and bloating. Primary approaches include prokinetic agents that enhance gastric motility, antiemetics to control nausea, and dietary modifications for symptom relief. For severe cases, gastric electrical stimulation may be used. As gastroparesis is commonly linked to diabetes and is often underdiagnosed, early diagnosis and targeted treatments are essential for effective management.
Gastroparesis Treatment Market- Market Dynamics
Increasing prevalence of diabetes globally to propel market demand
As diabetes is a major cause of gastroparesis, the global increase in diabetes cases fuels demand for gastroparesis treatments. The International Diabetes Federation reports that 537 million adults were living with diabetes in 2021, with numbers projected to rise to 643 million by 2030. Besides, as gastroparesis is more common in older adults, the global increase in the aging population supports demand for gastroparesis treatment. However, current gastroparesis treatments focus on symptom management rather than curing the condition, which limits effectiveness and leads to patient dissatisfaction. This may hamper the market growth in the coming years. On the contrary, ongoing research into the underlying causes of gastroparesis, increasing awareness campaigns, and advancements in diagnostic tools to improve early detection are all expected to provide massive growth opportunities for the global gastroparesis treatment market during the forecast period.
Gastroparesis Treatment Market- Key Insights
As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 4.77% over the forecast period (2024-2032)
Based on drug class segmentation, prokinetic drugs was predicted to show maximum market share in the year 2023
Based on type segmentation, prescription drugs was the leading segment in 2023
Based on route of administration segmentation, oral was the leading type in 2023
Based on disease indication segmentation, diabetes gastroparesis was the leading segment in 2023
Based on distribution channel segmentation, hospital pharmacies was the leading segment in 2023
On the basis of region, the North America gastroparesis treatment market was the leading revenue generator in 2023
Gastroparesis Treatment Market- Segmentation Analysis:
The Global Gastroparesis Treatment Market is segmented on the basis of Drug Class, Type, Route of Administration, Disease Indication, Distribution Channel, and Region.
The market is divided into four categories based on drug class: antiemetic drugs, prokinetic agents, proton pump inhibitors, and others. Prokinetic agents are crucial in the treatment of gastroparesis as they enhance stomach muscle contractions, alleviating symptoms like nausea and improving digestion. Their effectiveness extends beyond gastroparesis and studies have shown that they also help critical patients receiving enteral nutrition, reducing feeding intolerance.
The global gastroparesis treatment market is divided into two categories based on type: prescription drugs and over-the-counter drugs. The prescription drugs sector is likely to dominate the market during the forecast period. This is due to the rising prevalence of gastroparesis and the growing demand for effective treatments. Prescription medications are often more potent and specifically tailored to address the complexities of the condition, which drives their adoption among healthcare providers and patients.
Gastroparesis Treatment Market- Geographical Insights
Geographically, this market is widespread into the regions of North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. These regions are further divided as per the nations bringing business.
Gastroparesis Treatment Market- Competitive Landscape:
The increasing prevalence of gastroparesis is creating a competitive landscape focused on innovative treatment options. Companies are prioritizing research and development to introduce advanced therapies, including prokinetic agents and dietary management solutions. Collaborations with healthcare professionals and research institutions enhance treatment effectiveness and foster the adoption of the latest clinical practices. Additionally, raising awareness through educational initiatives is essential for improving early diagnosis and patient adherence to treatments. The trend towards personalized medicine is also emerging, allowing for tailored treatment plans that better address individual patient needs.
Recent Developments:
In June 2024, Renexxion Ireland Limited, a biopharmaceutical company focused on gastrointestinal treatments, has gained FDA approval for its Investigational New Drug application for naronapride. This oral drug targets gastroparesis, a disorder causing delayed stomach emptying with symptoms like nausea and vomiting, affecting millions in the U.S., Europe, and Australia.
SCOPE OF THE REPORT
The scope of this report covers the market by its major segments, which include as follows:
GLOBAL GASTROPARESIS TREATMENT MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS
- Medtronic plc
- Abbott Laboratories
- Salix Pharmaceuticals, Inc.
- Kimberly-Clark Corporation
- C. R. Bard, Inc
- Boston Scientific Corporation
- Janssen Global Services LLC
- Alfa Wassermann SPA
- AbbVie Inc.
- Evoke Pharma
- Cardinal Health, Inc.
- Rhythm Pharmaceuticals, Inc.
- GlaxoSmithKline Plc
- Bausch Health
- Neurogastrx, Inc.
- Theravance Biopharma
- AstraZeneca Plc
- Cipla Limited
- Pfizer, Inc.
- Teva Pharmaceutical Industries Limited
- The Takeda Pharmaceutical Company Ltd.
- Processa Pharmaceuticals, Inc.
- Vanda Pharmaceuticals, Inc.
- Otsuka Holdings Co. Ltd.
- ANI Pharmaceuticals, Inc.
- CinDome Pharma, Inc.
- PTC Therapeutics
- Ironwood Pharmaceuticals, Inc.
- Others
GLOBAL GASTROPARESIS TREATMENT MARKET, BY DRUG CLASS- MARKET ANALYSIS, 2019 - 2032
- Antiemetic Drugs
- Prokinetic Agents
- Proton Pump Inhibitors
- Others
GLOBAL GASTROPARESIS TREATMENT MARKET, BY TYPE- MARKET ANALYSIS, 2019 - 2032
- Prescription Drugs
- Over-the-Counter Drugs
GLOBAL GASTROPARESIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION- MARKET ANALYSIS, 2019 - 2032
- Nasal
- Injectables
- Oral
GLOBAL GASTROPARESIS TREATMENT MARKET, BY DISEASE INDIATION- MARKET ANALYSIS, 2019 - 2032
- Idiopathic Gastroparesis
- Diabetes Gastroparesis
- Post-surgical Gastroparesis
GLOBAL GASTROPARESIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL- MARKET ANALYSIS, 2019 - 2032
- Online Pharmacies
- Retail Pharmacies
- Hospital Pharmacies
GLOBAL GASTROPARESIS TREATMENT MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032
- North America
- The U.S.
- Canada
- Europe
- Germany
- France
- Italy
- Spain
- United Kingdom
- Russia
- Netherlands
- Sweden
- Poland
- Rest of Europe
- Asia Pacific
- India
- China
- South Korea
- Japan
- Australia
- Thailand
- Indonesia
- Philippines
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Argentina
- Colombia
- Rest of LATAM
- The Middle East and Africa
- Saudi Arabia
- United Arab Emirates
- Israel
- Turkey
- Algeria
- Egypt
- Rest of MEA
Table of Contents
1. Gastroparesis Treatment Market Overview
- 1.1. Study Scope
- 1.2. Market Estimation Years
2. Executive Summary
- 2.1. Market Snippet
- 2.1.1. Gastroparesis Treatment Market Snippet by Drug Class
- 2.1.2. Gastroparesis Treatment Market Snippet by Type
- 2.1.3. Gastroparesis Treatment Market Snippet by Route of Administration
- 2.1.4. Gastroparesis Treatment Market Snippet by Disease Indication
- 2.1.5. Gastroparesis Treatment Market Snippet by Distribution Channel
- 2.1.6. Gastroparesis Treatment Market Snippet by Country
- 2.1.7. Gastroparesis Treatment Market Snippet by Region
- 2.2. Competitive Insights
3. Gastroparesis Treatment Key Market Trends
- 3.1. Gastroparesis Treatment Market Drivers
- 3.1.1. Impact Analysis of Market Drivers
- 3.2. Gastroparesis Treatment Market Restraints
- 3.2.1. Impact Analysis of Market Restraints
- 3.3. Gastroparesis Treatment Market Opportunities
- 3.4. Gastroparesis Treatment Market Future Trends
4. Gastroparesis Treatment Industry Study
- 4.1. PEST Analysis
- 4.2. Porter's Five Forces Analysis
- 4.3. Growth Prospect Mapping
- 4.4. Regulatory Framework Analysis
5. Gastroparesis Treatment Market: Impact of Escalating Geopolitical Tensions
- 5.1. Impact of COVID-19 Pandemic
- 5.2. Impact of Russia-Ukraine War
- 5.3. Impact of Middle East Conflicts
6. Gastroparesis Treatment Market Landscape
- 6.1. Gastroparesis Treatment Market Share Analysis, 2023
- 6.2. Breakdown Data, by Key Manufacturer
- 6.2.1. Established Players' Analysis
- 6.2.2. Emerging Players' Analysis
7. Gastroparesis Treatment Market - By Drug Class
- 7.1. Overview
- 7.1.1. Segment Share Analysis, By Drug Class, 2023 & 2032 (%)
- 7.1.2. Antiemetic Drugs
- 7.1.3. Prokinetic Agents
- 7.1.4. Proton Pump Inhibitors
- 7.1.5. Others
8. Gastroparesis Treatment Market - By Type
- 8.1. Overview
- 8.1.1. Segment Share Analysis, By Type, 2023 & 2032 (%)
- 8.1.2. Prescription Drugs
- 8.1.3. Over-the-Counter Drugs
9. Gastroparesis Treatment Market - By Route of Administration
- 9.1. Overview
- 9.1.1. Segment Share Analysis, By Route of Administration, 2023 & 2032 (%)
- 9.1.2. Nasal
- 9.1.3. Injectables
- 9.1.4. Oral
10. Gastroparesis Treatment Market - By Disease Indication
- 10.1. Overview
- 10.1.1. Segment Share Analysis, By Disease Indication, 2023 & 2032 (%)
- 10.1.2. Idiopathic Gastroparesis
- 10.1.3. Diabetes Gastroparesis
- 10.1.4. Post-surgical Gastroparesis
11. Gastroparesis Treatment Market - By Distribution Channel
- 11.1. Overview
- 11.1.1. Segment Share Analysis, By Distribution Channel, 2023 & 2032 (%)
- 11.1.2. Online Pharmacies
- 11.1.3. Retail Pharmacies
- 11.1.4. Hospital Pharmacies
12. Gastroparesis Treatment Market- By Geography
- 12.1. Introduction
- 12.1.1. Segment Share Analysis, By Geography, 2023 & 2032 (%)
- 12.2. North America
- 12.2.1. Overview
- 12.2.2. Gastroparesis Treatment Key Manufacturers in North America
- 12.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 12.2.4. North America Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 12.2.5. North America Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
- 12.2.6. North America Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 12.2.7. North America Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
- 12.2.8. North America Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 12.2.9. U.S.
- 12.2.9.1. Overview
- 12.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 12.2.9.3. U.S. Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 12.2.9.4. U.S. Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
- 12.2.9.5. U.S. Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 12.2.9.6. U.S. Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
- 12.2.9.7. U.S. Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 12.2.10. Canada
- 12.2.10.1. Overview
- 12.2.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 12.2.10.3. Canada Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 12.2.10.4. Canada Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
- 12.2.10.5. Canada Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 12.2.10.6. Canada Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
- 12.2.10.7. Canada Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 12.3. Europe
- 12.3.1. Overview
- 12.3.2. Gastroparesis Treatment Key Manufacturers in Europe
- 12.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 12.3.4. Europe Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 12.3.5. Europe Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
- 12.3.6. Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 12.3.7. Europe Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
- 12.3.8. Europe Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 12.3.9. Germany
- 12.3.9.1. Overview
- 12.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 12.3.9.3. Germany Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 12.3.9.4. Germany Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
- 12.3.9.5. Germany Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 12.3.9.6. Germany Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
- 12.3.9.7. Germany Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 12.3.10. Italy
- 12.3.10.1. Overview
- 12.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 12.3.10.3. Italy Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 12.3.10.4. Italy Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
- 12.3.10.5. Italy Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 12.3.10.6. Italy Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
- 12.3.10.7. Italy Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 12.3.11. United Kingdom
- 12.3.11.1. Overview
- 12.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 12.3.11.3. United Kingdom Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 12.3.11.4. United Kingdom Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
- 12.3.11.5. United Kingdom Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 12.3.11.6. United Kingdom Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
- 12.3.11.7. United Kingdom Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 12.3.12. France
- 12.3.12.1. Overview
- 12.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 12.3.12.3. France Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 12.3.12.4. France Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
- 12.3.12.5. France Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 12.3.12.6. France Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
- 12.3.12.7. France Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 12.3.13. Russia
- 12.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 12.3.13.2. Russia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 12.3.13.3. Russia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
- 12.3.13.4. Russia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 12.3.13.5. Russia Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
- 12.3.13.6. Russia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 12.3.14. Netherlands
- 12.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 12.3.14.2. Netherlands Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 12.3.14.3. Netherlands Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
- 12.3.14.4. Netherlands Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 12.3.14.5. Netherlands Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
- 12.3.14.6. Netherlands Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 12.3.15. Sweden
- 12.3.15.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 12.3.15.2. Sweden Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 12.3.15.3. Sweden Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
- 12.3.15.4. Sweden Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 12.3.15.5. Sweden Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
- 12.3.15.6. Sweden Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 12.3.16. Poland
- 12.3.16.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 12.3.16.2. Poland Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 12.3.16.3. Poland Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
- 12.3.16.4. Poland Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 12.3.16.5. Poland Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
- 12.3.16.6. Poland Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 12.3.17. Rest of Europe
- 12.3.17.1. Overview
- 12.3.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 12.3.17.3. Rest of the Europe Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 12.3.17.4. Rest of the Europe Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
- 12.3.17.5. Rest of the Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 12.3.17.6. Rest of the Europe Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
- 12.3.17.7. Rest of the Europe Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 12.4. Asia Pacific (APAC)
- 12.4.1. Overview
- 12.4.2. Gastroparesis Treatment Key Manufacturers in Asia Pacific
- 12.4.3. Asia Pacific Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 12.4.4. Asia Pacific Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 12.4.5. Asia Pacific Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
- 12.4.6. Asia Pacific Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 12.4.7. Asia Pacific Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
- 12.4.8. Asia Pacific Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 12.4.9. India
- 12.4.9.1. Overview
- 12.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 12.4.9.3. India Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 12.4.9.4. India Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
- 12.4.9.5. India Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 12.4.9.6. India Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
- 12.4.9.7. India Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 12.4.10. China
- 12.4.10.1. Overview
- 12.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 12.4.10.3. China Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 12.4.10.4. China Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
- 12.4.10.5. China Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 12.4.10.6. China Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
- 12.4.10.7. China Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 12.4.11. Japan
- 12.4.11.1. Overview
- 12.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 12.4.11.3. Japan Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 12.4.11.4. Japan Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
- 12.4.11.5. Japan Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 12.4.11.6. Japan Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
- 12.4.11.7. Japan Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 12.4.12. South Korea
- 12.4.12.1. Overview
- 12.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 12.4.12.3. South Korea Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 12.4.12.4. South Korea Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
- 12.4.12.5. South Korea Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 12.4.12.6. South Korea Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
- 12.4.12.7. South Korea Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 12.4.13. Australia
- 12.4.13.1. Overview
- 12.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 12.4.13.3. Australia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 12.4.13.4. Australia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
- 12.4.13.5. Australia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 12.4.13.6. Australia Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
- 12.4.13.7. Australia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 12.4.14. Thailand
- 12.4.14.1. Overview
- 12.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 12.4.14.3. Thailand Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 12.4.14.4. Thailand Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
- 12.4.14.5. Thailand Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 12.4.14.6. Thailand Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
- 12.4.14.7. Thailand Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 12.4.15. Indonesia
- 12.4.15.1. Overview
- 12.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 12.4.15.3. Indonesia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 12.4.15.4. Indonesia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
- 12.4.15.5. Indonesia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 12.4.15.6. Indonesia Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
- 12.4.15.7. Indonesia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 12.4.16. Philippines
- 12.4.16.1. Overview
- 12.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 12.4.16.3. Philippines Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 12.4.16.4. Philippines Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
- 12.4.16.5. Philippines Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 12.4.16.6. Philippines Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
- 12.4.16.7. Philippines Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 12.4.17. Rest of APAC
- 12.4.17.1. Overview
- 12.4.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 12.4.17.3. Rest of APAC Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 12.4.17.4. Rest of APAC Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
- 12.4.17.5. Rest of APAC Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 12.4.17.6. Rest of APAC Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
- 12.4.17.7. Rest of APAC Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 12.5. Latin America
- 12.5.1. Overview
- 12.5.2. Gastroparesis Treatment Key Manufacturers in Latin America
- 12.5.3. Latin America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 12.5.4. Latin America Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 12.5.5. Latin America Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
- 12.5.6. Latin America Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 12.5.7. Latin America Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
- 12.5.8. Latin America Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 12.5.9. Brazil
- 12.5.9.1. Overview
- 12.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 12.5.9.3. Brazil Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 12.5.9.4. Brazil Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
- 12.5.9.5. Brazil Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 12.5.9.6. Brazil Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
- 12.5.9.7. Brazil Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 12.5.10. Mexico
- 12.5.10.1. Overview
- 12.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 12.5.10.3. Mexico Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 12.5.10.4. Mexico Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
- 12.5.10.5. Mexico Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 12.5.10.6. Mexico Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
- 12.5.10.7. Mexico Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 12.5.11. Argentina
- 12.5.11.1. Overview
- 12.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 12.5.11.3. Argentina Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 12.5.11.4. Argentina Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
- 12.5.11.5. Argentina Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 12.5.11.6. Argentina Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
- 12.5.11.7. Argentina Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 12.5.12. Colombia
- 12.5.12.1. Overview
- 12.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 12.5.12.3. Colombia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 12.5.12.4. Colombia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
- 12.5.12.5. Colombia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 12.5.12.6. Colombia Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
- 12.5.12.7. Colombia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 12.5.13. Rest of LATAM
- 12.5.13.1. Overview
- 12.5.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 12.5.13.3. Rest of LATAM Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 12.5.13.4. Rest of LATAM Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
- 12.5.13.5. Rest of LATAM Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 12.5.13.6. Rest of LATAM Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
- 12.5.13.7. Rest of LATAM Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 12.6. Middle East and Africa
- 12.6.1. Overview
- 12.6.2. Gastroparesis Treatment Key Manufacturers in Middle East and Africa
- 12.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 12.6.4. Middle East and Africa Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 12.6.5. Middle East and Africa Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
- 12.6.6. Middle East and Africa Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 12.6.7. Middle East and Africa Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
- 12.6.8. Middle East and Africa Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 12.6.9. Saudi Arabia
- 12.6.9.1. Overview
- 12.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 12.6.9.3. Saudi Arabia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 12.6.9.4. Saudi Arabia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
- 12.6.9.5. Saudi Arabia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 12.6.9.6. Saudi Arabia Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
- 12.6.9.7. Saudi Arabia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 12.6.10. United Arab Emirates
- 12.6.10.1. Overview
- 12.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 12.6.10.3. United Arab Emirates Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 12.6.10.4. United Arab Emirates Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
- 12.6.10.5. United Arab Emirates Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 12.6.10.6. United Arab Emirates Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
- 12.6.10.7. United Arab Emirates Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 12.6.11. Israel
- 12.6.11.1. Overview
- 12.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 12.6.11.3. Israel Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 12.6.11.4. Israel Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
- 12.6.11.5. Israel Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 12.6.11.6. Israel Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
- 12.6.11.7. Israel Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 12.6.12. Turkey
- 12.6.12.1. Overview
- 12.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 12.6.12.3. Turkey Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 12.6.12.4. Turkey Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
- 12.6.12.5. Turkey Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 12.6.12.6. Turkey Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
- 12.6.12.7. Turkey Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 12.6.13. Algeria
- 12.6.13.1. Overview
- 12.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 12.6.13.3. Algeria Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 12.6.13.4. Algeria Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
- 12.6.13.5. Algeria Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 12.6.13.6. Algeria Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
- 12.6.13.7. Algeria Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 12.6.14. Egypt
- 12.6.14.1. Overview
- 12.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 12.6.14.3. Egypt Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 12.6.14.4. Egypt Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
- 12.6.14.5. Egypt Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 12.6.14.6. Egypt Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
- 12.6.14.7. Egypt Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 12.6.15. Rest of MEA
- 12.6.15.1. Overview
- 12.6.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 12.6.15.3. Rest of MEA Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 12.6.15.4. Rest of MEA Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
- 12.6.15.5. Rest of MEA Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 12.6.15.6. Rest of MEA Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
- 12.6.15.7. Rest of MEA Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
13. Key Vendor Analysis- Gastroparesis Treatment Industry
- 13.1. Competitive Dashboard
- 13.1.1. Competitive Benchmarking
- 13.1.2. Competitive Positioning
- 13.2. Company Profiles
- 13.2.1. Medtronic plc
- 13.2.2. Abbott Laboratories
- 13.2.3. Salix Pharmaceuticals, Inc.
- 13.2.4. Kimberly-Clark Corporation
- 13.2.5. C. R. Bard, Inc
- 13.2.6. Boston Scientific Corporation
- 13.2.7. Janssen Global Services LLC
- 13.2.8. Alfa Wassermann SPA
- 13.2.9. AbbVie Inc.
- 13.2.10. Evoke Pharma
- 13.2.11. Cardinal Health, Inc.
- 13.2.12. Rhythm Pharmaceuticals, Inc.
- 13.2.13. GlaxoSmithKline Plc
- 13.2.14. Bausch Health
- 13.2.15. Neurogastrx, Inc.
- 13.2.16. Theravance Biopharma
- 13.2.17. AstraZeneca Plc
- 13.2.18. Cipla Limited
- 13.2.19. Pfizer, Inc.
- 13.2.20. Teva Pharmaceutical Industries Limited
- 13.2.21. The Takeda Pharmaceutical Company Ltd.
- 13.2.22. Processa Pharmaceuticals, Inc.
- 13.2.23. Vanda Pharmaceuticals, Inc.
- 13.2.24. Otsuka Holdings Co. Ltd.
- 13.2.25. ANI Pharmaceuticals, Inc.
- 13.2.26. CinDome Pharma, Inc.
- 13.2.27. PTC Therapeutics
- 13.2.28. Ironwood Pharmaceuticals, Inc.
- 13.2.29. Others
14. 360 Degree Analyst View
15. Appendix
- 15.1. Research Methodology
- 15.2. References
- 15.3. Abbreviations
- 15.4. Disclaimer
- 15.5. Contact Us
샘플 요청 목록